We confirmed by FISH that the tumor harbored an ALK rearrangement, but the ALK-IHC score was zero during chemotherapy, and crizotinib was administered as second-line chemotherapy; after 8 weeks, the disease had progressed. The gene discussed is ALK; the disease is neoplasm.